SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
SEC Accession No. 0001193125-20-267267
Filing Date
2020-10-09
Accepted
2020-10-09 16:44:53
Documents
6
Effectiveness Date
2020-10-09

Document Format Files

Seq Description Document Type Size
1 DEFM14A d63221ddefm14a.htm DEFM14A 1065336
2 GRAPHIC g63221g02e03.jpg GRAPHIC 15228
3 GRAPHIC g63221g47r07.jpg GRAPHIC 58829
4 GRAPHIC g63221g73g64.jpg GRAPHIC 66464
5 GRAPHIC g63221page110.jpg GRAPHIC 119164
6 GRAPHIC g63221page111.jpg GRAPHIC 161429
  Complete submission text file 0001193125-20-267267.txt   1647071
Mailing Address 200 CAMBRIDGE PARK DRIVE SUITE 3100 CAMBRIDGE MA 02140
Business Address 200 CAMBRIDGE PARK DRIVE SUITE 3100 CAMBRIDGE MA 02140 617-945-5576
Cogent Biosciences, Inc. (Filer) CIK: 0001622229 (see all company filings)

IRS No.: 465308248 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFM14A | Act: 34 | File No.: 001-38443 | Film No.: 201233693
SIC: 2834 Pharmaceutical Preparations